SAB Biotherapeutics, Inc.
SABS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 87 institutions reported holding it in 13F filings for Q2 2026, worth $266.8M in total; no superinvestor holds it.
Other share classesSABSW
Holders of 5% or more of SABS
Holders whose latest Schedule 13D or 13G filing reports 5% or more of SAB Biotherapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. | 13G | 9.99%25.9M shares | New | Oct 3, 20251 filing | Oct 3, 2025 | SEC |
| Ra Capital Management, L.P. | 13D/A | 9.90%7.31M shares | 0.00 ppfrom 9.90% | Oct 3, 20253 filings | Mar 23, 2026 | SEC |
| Woodline Partners LP | 13G | 9.90%7.13M shares | New | Nov 14, 20251 filing | Nov 14, 2025 | SEC |
| Commodore Capital LP | 13G | 9.90%4.52M shares | New | Oct 3, 20251 filing | Oct 3, 2025 | SEC |
| Biotechnology Value Fund L P | 13G/A | 9.10%4.76M shares | −0.89 ppfrom 9.99% | Nov 14, 20252 filings | Feb 17, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
10 Schedule 13D and 13G filings on SAB Biotherapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 23, 20264:25 PM ET | Ra Capital Management, L.P.and 3 others | 13D/A | 9.90%7.31M shares | 0.00 ppfrom 9.90% | Mar 19, 2026 | SEC |
| Mar 11, 20264:43 PM ET | Ra Capital Management, L.P.and 3 others | 13D/A | 9.90%5.17M shares | 0.00 ppfrom 9.90% | Mar 9, 2026 | SEC |
| Feb 17, 20264:23 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 9.10%4.76M shares | −0.89 ppfrom 9.99% | Dec 31, 2025 | SEC |
| Feb 17, 20268:47 AM ET | RTW Investments, LPand 1 other | 13G/A | 3.20%1.59M shares | −6.79 ppfrom 9.99%Below 5% | Dec 31, 2025 | SEC |
| Nov 14, 20254:24 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 9.99%5.17M shares | – | Sep 30, 2025 | SEC |
| Nov 14, 20254:18 PM ET | Woodline Partners LP | 13G | 9.90%7.13M shares | New | Sep 30, 2025 | SEC |
| Oct 3, 20254:30 PM ET | Vivo Opportunity Fund Holdings, L.P.and 3 others | 13G | 9.99%25.9M shares | New | Sep 29, 2025 | SEC |
| Oct 3, 20254:26 PM ET | Ra Capital Management, L.P.and 3 others | 13D | 9.90%4.40M shares | New | Sep 26, 2025 | SEC |
| Oct 3, 20254:05 PM ET | Commodore Capital LPand 3 others | 13G | 9.90%4.52M shares | New | Sep 26, 2025 | SEC |
| Feb 14, 20259:00 AM ET | RTW Investments, LPand 1 other | 13G/A | 9.99%1.02M shares | – | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell SAB Biotherapeutics, Inc. shares.
No Form 144 notices for SAB Biotherapeutics, Inc. are on file.